Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774758 · ClinicalTrials.gov registry record
Biomarkers for Risk Stratification in Lung Cancer
A clinical trial of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 590
- Enrollment target
- 3
- Study locations
NCT03774758: Recruiting study of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary, sponsored by University of California, San Francisco.
NCT03774758 is a study of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 590 participants, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03774758, a study of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 590 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Primary Outcome
Estimation of the ctDNA assay's clinical sensitivity and specificity in patients with lung cancer as proven by histology or tumor board consensus opinion\* and in patients with lung nodule ≥6 mm but without cancer as proven by extended CT screening follow-up\*\*. \*Patients may be treated with curative-intent Stereotactic Body Radiotherapy (SBRT) without tissue confirmation IF pretest probability for lung cancer by tumor board consensus opinion is ≥90% and the biopsy risk is high.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Guardant Health ct-DNA LUNAR assay
Study Locations (3)
California
- Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
- San Francisco VA Medical Center - San Francisco
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2017-12-17 |
| Est. Completion | 2025-12-31 |
What NCT03774758 shows while recruiting
NCT03774758 is an observational study that tracks outcomes without assigning an intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Guardant Health ct-DNA LUNAR assay is the first listed.
NCT03774758 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03774758 about?
NCT03774758 is a clinical study titled "Biomarkers for Risk Stratification in Lung Cancer". This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populat...
What is the current status of trial NCT03774758?
This trial is currently recruiting. The enrollment target is 590 participants. The study started on 2017-12-17. Estimated completion is 2025-12-31.
What conditions does trial NCT03774758 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Nodule Solitary Pulmonary.
What interventions are being tested in trial NCT03774758?
The interventions under investigation include: Guardant Health ct-DNA LUNAR assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03774758?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03774758 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03774758's enrollment target sits among peer trials
590 61st of 454 higher than 394 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
- NCT06551142 · 590 participants · Phase 1
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI